Citations

Clear

3942 citation(s) found for "To, Van".

Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference
Kloske, Courtney M. , Blue, Elizabeth , Carrillo, María C. , Chen, Xiaoying , Chiba‐Falek, Ornit , Davis, Albert A. , Paolo, Gilbert Di , Garretti, Francesca , Golden, Lesley R. , Heinecke, Jay W. , Herz, Joachim, Huang, Yadong , Kanekiyo, Takahisa , Khvorova, Anastasia, Hertog, Sascha J. Koppes‐den, Lamb, Bruce T. , Lawler, Paige E. , Litvinchuk, Alexandra , Liu, Chia‐Chen , Michaelson, D. M., Miller, Justin J. , Morganti, Josh M. , Oosthoek, Marlies , Ramachandran, Kapil V. , Ramakrishnan, Abhirami , Robert, Aiko, Sexton, Claire E. , Shah, Nilomi, Shue, Francis , Strickland, Michael R. , TCW, Julia , Thierry, Manon, Tuckey, Ryan A. , Ulrich, Jason D. , Wang, Na , Weninger, Stacie, Zhao, Na , Goate, Alison , Liu, Chia-Chen , Shue, Francis , Zhao, Na , Goate, Alison M , Belloy, Michaël E. , Bowman, Gregory R. , Gate, David M , Iadecola, Costantino , Johnson, Lance A. , Karch, Celeste M. , Khvorova, Anastasia , Hertog, Sascha Koppes-den , Le Guen, Yann , Mahinrad, Simin , Marcora, Edoardo , Mariño, Claudia , Narayan, Priyanka , Naslavsky, Michel Satya , Raulin, Ana‐Caroline , Saleh, Rasha N.M. , Sible, Isabel J. , Soranno, Andrea , Tsai, Li‐Huei , Kant, Rik van der , Wellington, Cheryl L. , Yassine, Hussein N. , Bu, Guojun , Holtzman, David M.

Mayo Clinic

Alzheimer's & Dementia | July 19, 2024 | Volume: 20 | Issue: 9 | Pages: 6590-6605

10.1002/alz.13877 | PMID 39031528 Get It

AbstractINTRODUCTIONThe apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer's disease (AD), with distinct apoE isoforms exerting diverse effects. apoE influences not only amyloid‐beta and tau pathologies but also lipid and energy metabolism, neuroinflammation, cerebral vascular health, and sex‐dependent disease manifestations. Furthermore, ancestral background may significantly impact the link between APOE and AD, underscoring the need for more inclusive research.METHODSIn 2023, the Alzheimer's Association convened multidisciplinary researchers at the “AAIC Advancements: APOE” conference to discuss various topics, including apoE isoforms and their roles in AD pathogenesis, progress in apoE‐targeted therapeutic strategies, updates on disease models and interventions that modulate apoE expression and function.RESULTSThis manuscript presents highlights from the conference and provides an overview of opportunities for further research in the field.DISCUSSIONUnderstanding apoE's multifaceted roles in AD pathogenesis will help develop targeted interventions for AD and advance the field of AD precision medicine.Highlights APOE is a central player in the pathogenesis of Alzheimer's disease. APOE exerts a numerous effects throughout the brain on amyloid‐beta, tau, and other pathways. The AAIC Advancements: APOE conference encouraged discussions and collaborations on understanding the role of APOE.
SupraPetrous InfraTemporal Approach: A Supplemental Approach to Supracerebellar Infratentorial for Inferior Amygdala and Hippocampal Head Access—A Cadaveric Study With Case Illustrations
Shinya, Yuki , Leonel, Luciano, Hong, Sukwoo , Nizzola, Mariagrazia , Meyer, Jenna H., Sáez-Alegre, Miguel , Kin, Taichi , Peris-Celda, Maria, Leonel, Luciano César P C, Moussalem, Charbel K, Serioli, Simona , De Bonis, Alessandro, Van Gompel, Jamie J , Shinya, Yuki , Moussalem, Charbel K. , Bonis, Alessandro De, Bauman, Megan M. J. , Peris‐Celda, Maria , Gompel, Jamie J. Van

Mayo Clinic

Operative Neurosurgery | July 16, 2024 | Volume: 28 | Issue: 3 | Pages: 399-406

10.1227/ons.0000000000001292 | PMID 39012126 Get It

BACKGROUND AND OBJECTIVES: Access to the amygdala and hippocampus (A/H) is complex. To address the limitations and invasiveness of traditional approaches, including the Transsylvian, Subtemporal, and Supracerebellar infratentorial approaches, we developed the suprapetrous infratemporal (SPIT) approach. This study describes the nuances of this approach in both cadaveric studies and clinical cases. METHODS: Three unilateral exposures were performed using microscopic and endoscopic methodologies in the SPIT approach. After cadaveric investigation, this approach was successfully implemented in representative clinical cases. RESULTS: The SPIT approach enabled direct access to the inferior A/H, circumventing the requirement for temporal lobe retraction and detachment of the temporal lobe from the dura through a subtemporal route by drilling the upper part of the mastoid, consequently mitigating tension on the vein of Labbé. This enabled a bottom-up view because one would gain with a zygomatic osteotomy and forward projection like a mini-posterior petrosal view by using a transmastoid view, without cutting down the zygomatic arch and opening the dura subtemporally, limiting patient pain and preventing case comorbidity. The SPIT approach was performed in 2 cases of mesial temporal cavernoma presenting with seizures. The lesion was visualized intraoperatively and was successfully removed in these cases. The postoperative course was excellent with no complications, and gross total resection was radiographically confirmed with Engel Class 1a seizure freedom. CONCLUSION: The SPIT approach is a complementary approach for inferior A/H disease, combining the combined middle fossa approach modified for intradural pathology. Limited drilling of the upper aspect of the mastoid with a medial dural opening at the level of the arcuate eminence provides a direct trajectory with minimal brain retraction. Additional research encompassing a larger patient cohort and extended follow-up periods is required to substantiate the advantages of SPIT in the management of inferior A/H lesions.
An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
Kapoor, Prashant , Pour, Luděk , Lichtman, Eben I. , Mateos, María‐Victoria , Kanagavel, Dheepak , Zhao, Liang , Guillemin‐Paveau, Hélène, Macé, Sandrine , Velde, Helgi van de , Richardson, Paul G. , Dimopoulos, Meletios A , Richardson, Paul Gerard Guy , Nathwani, Nitya , Jelı́nek, Tomáš , Perrot, Aurore , Dimopoulos, Meletios Α. , Huang, Shang‐Yi , Špıčka, Ivan , Chhabra, Saurabh

Mayo Clinic

European Journal of Haematology | July 12, 2024 | Volume: 113 | Issue: 5 | Pages: 593-605

10.1111/ejh.14270 | PMID 38993150 Get It

AbstractObjectivesCluster of differentiation 38 (CD38) is a key target on multiple myeloma (MM) cells. This multi‐centre, Phase 1, single‐agent study (NCT04000282) investigated SAR442085, a novel fragment crystallisable (Fc)‐modified anti‐CD38 monoclonal antibody (mAb), with enhanced affinity towards Fc‐gamma receptor on effector cells in patients with relapsed and/or refractory (RR) MM.MethodsThis study comprised two parts: Part‐A (dose‐escalation involving anti‐CD38 mAb pre‐treated and naïve patients) and Part‐B (dose expansion). Primary endpoints were maximum tolerated dose and recommended Phase 2 dose (RP2D).ResultsThirty‐seven heavily pre‐treated patients were treated in Part A. Part‐B (dose‐expansion) was not studied. Seven dose‐limiting toxicities were reported at DL3, DL5, DL6, and DL7. RP2D was determined to be 5–7·5 mg/kg. Most common treatment‐emergent adverse events were infusion‐related reactions in 70·3% (26/37) patients. Grade ≥3 thrombocytopenia was reported in 48·6% (18/37). Overall response rate was 70% in anti‐CD38 mAb naïve and 4% in anti‐CD38 pre‐treated patients, with a median progression‐free survival of 7·62 (95%CI: 2·858; not calculable) months and 2·79 (95%CI: 1·150; 4·172) months and, respectively.ConclusionsThe efficacy of SAR442085 was promising in anti‐CD38 mAb naïve patients but did not extend to the larger cohort of anti‐CD38 mAb pre‐treated patients. This observation, along with transient high‐grade thrombocytopenia, could potentially limit its clinical use.
Pilot Program in Surgical Anatomy Education for Complex Cranial and Skull Base Procedures: Curriculum Overview and Initial 2-Year Experience at Mayo Clinic
Capp, Juliana C., Bauman, Megan M. J. , Graffeo, Christopher S. , Carlstrom, Lucas P. , Perry, Avital , Gompel, Jamie J. Van , Link, Michael J., Leonel, Luciano, Celda, María Peris, Van Gompel, Jamie J , Bauman, Megan , Capp, Juliana C., Pinheiro‐Neto, Carlos , Daniels, David J. , Link, Michael J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | July 11, 2024 | Volume: 86 | Issue: 04 | Pages: 438-451

10.1055/a-2364-3189 | PMID 40620629 Get It

Abstract Background Cadaveric dissection remains a preferred and irreplaceable learning modality among neurosurgery residents. We aimed to develop and describe a tiered, quantifiable, and practical curriculum for cranial neurosurgical anatomy education. We report the structure and evaluation of our 2-year pilot study to serve as a suggested guide for other neurosurgery programs. Methods Our Complex Cranial Dissection Program is tailored to the needs of junior-level neurosurgery residents based on their postgraduation years 1 to 4. Dissections are performed in a sequential manner, each of which emphasize a particular set of manual skills and neuroanatomical knowledge. Dissections are scored on a scale of 10 points. The grading was based on specific landmarks and anatomical structures, which need to be exposed, explored, and preserved. Results Out of 16 residents, 14 individuals (87.5%) attended the dissections in the first iteration of the program and 16 individuals (100%) attended the dissections in the second iteration. A total of 17 dissections were performed across all years. In survey feedback about the program, 100% (Year 1) and 94% (Year 2) of residents considered the assigned dissections to be appropriate for their respective training levels. Further, 100% (Year 1) and 94% (Year 2) of residents endorsed that the dissections were important and helpful for their practice prior to similar operating room experiences. Conclusion The development and implementation of structured dissection programs within residency training, along with dedicated staff, and objective feedback serve a crucial role in neurosurgical education to further develop and enhance surgical skills in the operative setting.
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
Chien, A. Jo , Wei, Mei , Veer, Laura van 't, Alkhafaji, Silver , Chen, Nan , Borowsky, Alexander D. , Hylton, Nola, Mukhtar, Rita A. , Giridhar, Karthik V. , Olopade, Olufunmilayo I. , Kalinsky, Kevin M. , Vaklavas, Christos , Elias, Anthony , Goetz, Matthew P. , Rugo, Hope S. , Symmans, W. Fraser , Swigart, Lamorna Brown , Onishi, Natsuko , Yee, Douglas , Esserman, Laura J.

Mayo Clinic

Journal of Clinical Oncology | July 11, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 601-601

10.1200/jco.2024.42.16_suppl.601 Get It

601 Background: EOP is an I-SPY2 neoadjuvant sub-study designed to test the tolerability and impact of novel endocrine-based strategies in stage 2/3 BC pts predicted to have lower benefit from chemotherapy. Amcenestrant (A) is an oral selective estrogen receptor degrader (SERD) with activity in hormone receptor positive (HR+) HER2- metastatic BC. Methods: EOP eligibility included pts screened for the main I-SPY2 trial with HR+ HER2-, MammaPrint (MP) low risk Stage 2/3 BC. Pts with MP High risk tumor signatures were eligible if clinically node-negative (cN-). Pts were stratified by SET index and menopausal status. Pts were randomized to 3 arms: A 200 mg qd (A), A + abemaciclib 150 mg bid (AA), A + letrozole 2.5 mg qd (AL). Premenopausal pts received concurrent ovarian function suppression. Treatment was for 6 mos followed by surgery. Baseline (BL) and 3-wk biopsies were performed. Breast MRIs were conducted at BL (T0), 3 wks (T1), 12 wks (T2), 6 mos (T3). The primary endpoint was feasibility, defined as >75% of pts completing >75% study therapy. Results: Between May 2021 and Aug 2022, 74 pts were randomized: 31 A, 21 AA, 22 AL. Median age 50 years, 54% premenopausal, 38% clinically node-positive (cN+). 41% pts had ductal, 38% lobular, 11% mixed ductal/lobular histology. Mean BL tumor Ki67 (central testing) was 16.9%, 88% MP low, 76% SET index Hi. Pt and tumor characteristics were balanced across the 3 arms. Treatment in all 3 arms was feasible with 95% of pts completing >75% study therapy. Most common AEs include grade 1-2 hot flashes (69%) and fatigue (66%). Grade 3 AEs include neutropenia (2 pts) and diarrhea (1 pt) in AA. Table summarizes key response endpoints, which were similar between pre- and postmenopausal pts. Of 28 cN+ pts, 2 (7%) were pathologically node-negative (pN-). Mean MRI Functional Tumor Volume (cc) change between T0->T1, T1->T2, T2->T3, T0->T3 was -6.06 (-34.2%), -3.55 (-29.2%), -0.829 (-20.1%), -11.3 (-68.4%), respectively, similar across arms (p=0.396).ctDNA was detected in 10/59 (17%) pts at T0. ctDNA became undetectable in 6 pts, decreased in 4 pts, and went from ctDNA undetectable at baseline to detectable at T3 in 2 pts. Conclusions: Six months of neoadjuvant endocrine therapy (NET) with the oral SERD amcenestrant is feasible, well-tolerated, and demonstrates anti-proliferative and anti-tumor activity in pre- and postmenopausal pts. NET provides a rich platform for biomarker discovery and investigating response to endocrine therapy. Clinical trial information: NCT01042379 . [Table: see text]
Upper motor neuron‐predominant motor neuron disease presenting as atypical parkinsonism: A clinicopathological study
Murakami, Aya , Koga, Shunsuke , White, Adrianna, Bieniek, Kevin F. , Sekiya, Hiroaki , DeJesus‐Hernandez, Mariely, Finch, NiCole A., Blitterswijk, Marka van , Nakamura, Masataka , Tsuboi, Yoshio , White, Adrianna E, DeJesus-Hernandez, Mariely, Dickson, Dennis W , van Blitterswijk, Marka , Koga, Shunsuke , Sekiya, Hiroaki , Fujioka, Shinsuke , Murray, Melissa E. , Wszołek, Zbigniew K. , Dickson, Dennis W.

Mayo Clinic

Brain Pathology | July 11, 2024 | Volume: 35 | Issue: 1 | Pages: No page available

10.1111/bpa.13286 | PMID 38988008 Get It

AbstractAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by upper and lower motor neuron signs. There are, however, cases where upper motor neurons (UMNs) are predominantly affected, leading to clinical presentations of UMN‐dominant ALS or primary lateral sclerosis. Furthermore, cases exhibiting an UMN‐predominant pattern of motor neuron disease (MND) presenting with corticobasal syndrome (CBS) have been sparsely reported. This study aims to clarify the clinicopathological features of patients with UMN‐predominant MND. We reviewed 24 patients with UMN‐predominant MND with TDP‐43 pathology in the presence or absence of frontotemporal lobar degeneration. Additionally, we reviewed the medical records of patients with pathologically‐confirmed corticobasal degeneration (CBD) who received a final clinical diagnosis of CBS (n = 10) and patients with pathologically‐confirmed progressive supranuclear palsy (PSP) who received a final clinical diagnosis of PSP syndrome (n = 10). Of 24 UMN‐predominant MND patients, 20 had a clinical diagnosis of an atypical parkinsonian disorder, including CBS (n = 11) and PSP syndrome (n = 8). Only two patients had antemortem diagnoses of motor neuron disease. UMN‐predominant MND patients with CBS less frequently exhibited apraxia than those with CBD, and they were less likely to meet clinical criteria for possible or probable CBS. Similarly, UMN‐predominant MND patients with PSP syndrome less often met clinical criteria for probable PSP than PSP patients with PSP syndrome. Our findings suggest that UMN‐predominant MND can mimic atypical parkinsonism, and should be considered in the differential diagnosis of CBS and PSP syndrome, in particular when criteria are not met.
A phase 2 study of a brachyury‐targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma
Attia, Steven , Tine, Brian A. Van , Seetharam, ­Mahesh , Gafoor, Zarina, Heery, Christopher R., Pico-Navarro, Cesar, Adams, Tatiana , Van Tine, Brian A , Coté, Gregory M. , Conley, Anthony P. , Chen, Yen‐Lin

Mayo Clinic

Cancer | July 10, 2024 | Volume: 130 | Issue: 22 | Pages: 3845-3854

10.1002/cncr.35477 | PMID 38985843 Get It

AbstractBackgroundThis was a single‐arm, phase 2 clinical trial of Bavarian Nordic (BN)‐Brachyury vaccine plus radiotherapy (RT) designed to determine the objective response rate (ORR), progression‐free survival (PFS), and safety of the combination in chordoma.MethodsA total of 29 adult patients with advanced chordoma were treated with two subcutaneous priming vaccine doses of modified vaccinia Ankara‐Bavarian Nordic (MVA‐BN)‐Brachyury and one vaccine dose of fowlpox virus (FPV)‐Brachyury before RT. After RT, booster vaccinations were given with FPV‐Brachyury every 4 weeks for 4 doses, then every 12 weeks (week 110). A minimum RT dose of >8 Gy in one fraction for each target was required. Response was evaluated by modified Response Evaluation Criteria in Solid Tumors 1.1 (mRECIST), where only radiated lesions were considered targets, and by standard RECIST 1.1 in a subset of patients.ResultsTwo of 26 evaluable patients experienced durable partial response (PR) (ORR of 7.7%; 90% confidence interval [CI], 2.6–20.8]) by mRECIST 1.1. A total of 21 patients (80.8%; 90% CI, 65.4–90.3) had stable disease, and three patients (11.5%; 90% CI, 4.7–25.6) had progressive disease as best response per mRECIST 1.1. Median PFS was not reached during the study.ConclusionsThis trial confirms the safety of BN‐Brachyury and RT. Although the study did not meet the predefined study goal of four responses in 29 patients, we did observe two PRs and a PFS of greater than 2 years. For a vaccine‐based study in chordoma, an ultra‐rare disease where response rates are low, a randomized study or novel trial designs may be required to confirm activity.
Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study
Ulugut, Hülya , Samancı, Bedia , Illán‐Gala, Ignacio , Kuchcinski, Grégory , Leroy, Mélanie , Santillo, Alexander , Waldö, Maria Landqvist , Riedl, Lina , Stock, Jan Van den , Vandenbulcke, Mathieu , Ducharme, Simon , Pressman, Peter , Takada, Leonel Tadao , Diehl‐Schmid, Janine , Galimberti, Daniela , Barkhof, Frederik , Sturm, Virginia E. , Miyagawa, Toji , Whitwell, Jennifer L. , Rohrer, Jonathan D. , Gorno‐Tempini, Maria Luisa, Josephs, Keith A. , Warren, Jason D. , Rankin, Katherine P. , Group, International rtvFTD Working, Barkhof, Frederik , Rohrer, Jonathan D , Illán-Gala, Ignacio , Galimberti, Daniela , Bertoux, Maxime , Younes, Kyan , Montembeault, Maxime , Fumagalli, Giorgio , Thompson, J. C. , Kobylecki, Christopher , Englund, Elisabet , Vandenberghe, Rik , Laforce, Robert , Caramelli, Paulo , Souza, Leonardo Cruz de , Gurvit, Hakan I. , Hansson, Oskar , Pasquier, Florence , Miller, Bruce L. , Scheltens, Philip , Ossenkoppele, Rik , Flier, Wiesje M. van der , Fox, Nick C. , Boeve, Bradley F. , Gorno‐Tempini, Maria‐Luisa, Snowden, Julie S. , Pijnenburg, Yolande A.L. , Group, International rtvFTD Working

Mayo Clinic

Alzheimer's & Dementia | July 10, 2024 | Volume: 20 | Issue: 8 | Pages: 5647-5661

10.1002/alz.14076 | PMID 38982845 Get It

Abstract INTRODUCTION Although frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominance has been recognized, a uniform description of the syndrome is still missing. This multicenter study aims to establish a cohesive clinical phenotype. METHODS Retrospective clinical data from 18 centers across 12 countries yielded 360 FTD patients with predominant RATL atrophy through initial neuroimaging assessments. RESULTS Common symptoms included mental rigidity/preoccupations (78%), disinhibition/socially inappropriate behavior (74%), naming/word‐finding difficulties (70%), memory deficits (67%), apathy (65%), loss of empathy (65%), and face‐recognition deficits (60%). Real‐life examples unveiled impairments regarding landmarks, smells, sounds, tastes, and bodily sensations (74%). Cognitive test scores indicated deficits in emotion, people, social interactions, and visual semantics however, lacked objective assessments for mental rigidity and preoccupations. DISCUSSION This study cumulates the largest RATL cohort unveiling unique RATL symptoms subdued in prior diagnostic guidelines. Our novel approach, combining real‐life examples with cognitive tests, offers clinicians a comprehensive toolkit for managing these patients. Highlights This project is the first international collaboration and largest reported cohort. Further efforts are warranted for precise nomenclature reflecting neural mechanisms. Our results will serve as a clinical guideline for early and accurate diagnoses.
Peritoneal Dialysis Aggravates and Accelerates Atherosclerosis in Uremic ApoE −/− Mice
Kane, Jamie , Vos, Winnie G. , Bosmans, Laura A. , Os, Bram W. van , Toom, Myrthe den, Hoeksema‐Hackmann, Sanne, Wit, Denise Moen‐de, Gijbels, Marion J. , Beckers, Linda, Grefhorst, Aldo , Levels, Johannes H.M. , Jakulj, Lily , Vervloet, Marc G , Lutgens, Esther , Eringa, Etto C , van Os, Bram W , Kane, Jamie , Lutgens, Esther , Eringa, Etto C.

Mayo Clinic

Journal of the American Heart Association | July 9, 2024 | Volume: 13 | Issue: 14 | Pages: No page available

10.1161/jaha.123.034066 | PMID 38979792 Get It

Background Atherosclerosis is highly prevalent in people with chronic kidney disease (CKD), including those receiving peritoneal dialysis (PD). Although it is lifesaving, PD induces profound systemic inflammation, which may aggravate atherosclerosis. Therefore, the hypothesis is that this PD‐induced inflammation aggravates atherosclerosis via immune cell activation. Methods and Results ApoE −/− mice were subjected to a 5/6 nephrectomy to induce CKD. Three weeks later, mice were fed a high‐cholesterol diet. Half of the nephrectomized mice then received daily peritoneal infusions of 3.86% Physioneal for 67 further days (CKD+PD) until the end of the experiment, and were compared with mice without CKD. Sham operated and PD‐only mice were additional controls. CKD+PD mice displayed more severe atherosclerotic disease than control mice. Plaque area increased, and plaques were more advanced with a vulnerable phenotype typified by decreased collagen content and decreased fibrous cap thickness. Increased CD3 + T‐cell numbers were present in plaques and perivascular adipose tissue of CKD and CKD+PD mice. Plaques of CKD+PD mice contained more iNOS + immune cells. Spleens of CKD+PD mice showed more CD4 + central memory, terminally differentiated type 1 T‐helper (Th1), Th17, and CX3C motif chemokine receptor 1 + (CX3CR1) CD4 + T‐cells with less regulatory and effector T‐cells. Conclusions PD‐fluid exposure in uremic mice potentiates systemic and vascular T‐cell‐driven inflammation and aggravates atherosclerosis. PD polarized CD4 + T‐cells toward an inflammatory Th1/Th17 phenotype, and increased CX3CR1 + CD4 + T‐cells, which are associated with vascular homing in CKD‐associated atherosclerosis. Targeting CD4 + T‐cell activation and CX3CR1 + polarization has the potential to attenuate atherosclerosis in PD patients.
Avoiding the use of long‐term parenteral support in patients without intestinal failure: A position paper from the European Society of Clinical Nutrition & Metabolism, the European Society of Neurogastroenterology and Motility and the Rome Foundation f
Lal, Simon , Paine, Peter , Tack, Jan , Barazzoni, Rocco , Cuerda, Cristina , Lamprecht, Georg , Szczepanek, K., Gossum, A. Van, Wanten, G., Vanuytsel, Tim , Lal, S , Tack, Jan , Aziz, Qasim , Jeppesen, Palle Bekker , Joly, F. , Mundi, Manpreet S. , Schneider, Stephane , Pironi, Loris

Mayo Clinic

Neurogastroenterology & Motility | July 8, 2024 | Volume: 36 | Issue: 9 | Pages: No page available

10.1111/nmo.14853 | PMID 38973248 Get It

AbstractThe role of long‐term parenteral support in patients with underlying benign conditions who do not have intestinal failure (IF) is contentious, not least since there are clear benefits in utilising the oral or enteral route for nutritional support. Furthermore, the risks of long‐term home parenteral nutrition (HPN) are significant, with significant impacts on morbidity and mortality. There has, however, been a recent upsurge of the use of HPN in patients with conditions such as gastro‐intestinal neuromuscular disorders, opioid bowel dysfunction, disorders of gut–brain interaction and possibly eating disorders, who do not have IF. As a result, the European Society of Clinical Nutrition and Metabolism (ESPEN), the European Society of Neuro‐gastroenterology and Motility (ESNM) and the Rome Foundation for Disorders of Gut Brain Interaction felt that a position statement is required to clarify – and hopefully reduce the potential for harm associated with – the use of long‐term parenteral support in patients without IF. Consensus opinion is that HPN should not be prescribed for patients without IF, where the oral and/or enteral route can be utilised. On the rare occasions that PN commencement is required to treat life‐threatening malnutrition in conditions such as those listed above, it should only be prescribed for a time‐limited period to achieve nutritional safety, while the wider multi‐disciplinary team focus on more appropriate biopsychosocial holistic and rehabilitative approaches to manage the patient's primary underlying condition.